Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(17 sites)
United States
Precision NextGen Oncology, Beverly Hills, California SCRI at HealthOne, Denver, Colorado The Winship Cancer Institute of Emory University, Atlanta, Georgia MD Anderson Cancer Center, Houston, Texas China
Beijing Jishuitan Hospital, Beijing, Beijing Municipality The First Affiliated Hospital of Sun Yat-sen University, Guangdong, Guangzhou Hebei Medical University Third Hospital, Shijiazhuang, Hebei Henan Cancer Hospital, Zhengzhou, Henan The First Affiliated Hospital of Zhengzhou Universtity, Zhengzhou, Henan Jiangsu Province Hospital, Nanjing, Jiangsu Nanjing Drum Tower Hospital, Nanjing, Jiangsu Liaoning Cancer Hospital, Shenyang, Liaoning Huashan Hospital of Fudan University, Shanghai, Shanghai Municipality Shanghai Sixth People's Hospital, Shanghai, Shanghai Municipality Xi'an Hong Hui Hospital, Xian, Shanxi West China Hospital of Sichuan University, Chengdu, Sichuan The Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, Zhejiang